logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

UroGen Pharma Ltd. acquires next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc.

Feb 20, 2025•10 months ago

Acquiring Company

UroGen Pharma

Acquired Company

IconOVir Bio

PrincetonSan DiegoBiotechnologyHealthcareBiotechnology

Description

UroGen Pharma Ltd. expands its oncology pipeline portfolio through the acquisition of assets relating to a next-generation oncolytic virus ICVB-1042 from IconOVir Bio, Inc. In addition, UroGen also announced strategic research collaborations to explore the potential of its proprietary RTGel technology to enhance clinical effectiveness of multiple immunotherapies.

Company Information

Company

UroGen Pharma

Location

400 Alexander Park Drive

Princeton, New Jersey, United States

About

UroGen Pharma is a biotech company that builds novel solutions to revolutionize the way specialty cancers and urologic diseases are treated – because patients deserve better options. Our vision is grounded in our RTGel® drug delivery technology, our promising pipeline, and a collaborative drive for bold results.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed